Regulatory Blog

The traditional clinical trial model has long been associated with delays in data reporting, lengthy timelines, and inefficiencies in decision-making. Recognizing these challenges, the U.S. Food and Drug Administration (FDA) has taken a transformative step toward modernizing clinical research. This press announcement was released on April 28, 2026, marking a significant milestone in the evolution of clinical trials. The FDA introduced major steps to advance the implementation

The Singapore Health Sciences Authority (HSA) has released Version 6 of its updated guidance document titled “Post-Marketing Vigilance Requirements for Therapeutic Products and Cell, Tissue and Gene Therapy Products (CTGTP)”, effective from 1 April 2026. The updated guidance provides important clarification on pharmacovigilance obligations, adverse event reporting, risk management plans (RMPs), and post-registration safety responsibilities for companies operating in Singapore

The Philippines Food and Drug Administration (FDA) is advancing its regulatory framework by adopting internationally aligned practices to improve the quality, transparency, and efficiency of pharmaceutical product regulation. The draft circular Adoption and Implementation of Good Registration Management (GRM), Good Review Practice (GRevP), and Good Submission Practice (GSubP) for Pharmaceutical Products introduces a structured and integrated approach to both regulatory submi

Medicine shortages and discontinuations are a growing global concern, and Australia has established a robust regulatory framework to ensure early detection, transparency, and risk mitigation. The guidance Reporting a shortage or discontinuation of a medicine you supply (updated 13 April 2026) outlines the mandatory obligations for sponsors to report medicine shortages and discontinuations to the Therapeutic Goods Administration (TGA). A medicine shortage occurs when supply is

The European Union continues to strengthen its medical device regulatory framework through updated guidance on device classification, nomenclature (EMDN), and supply chain transparency. These updates aim to improve regulatory clarity, traceability, and patient safety, particularly under the MDR and IVDR frameworks. Key developments include the Update – MDCG 2021-24 Rev.1: Guidance on classification of medical devices (April 2026), alongside supporting guidance documents on EM

The European Medicines Agency (EMA) continues to advance data standardisation and digital transformation in regulatory processes through the implementation of ISO IDMP standards and Product Management Services (PMS). The guidance Process for the electronic submission of medicinal product information – Chapter 3 (Version 3.5, updated 20 April 2026) provides detailed instructions on how medicinal product data should be submitted, managed, and maintained electronically throughou

The European Medicines Agency (EMA) continues to strengthen transparency, data sharing, and international regulatory collaboration through its Clinical Data Publication (CDP) framework. A key development in this area is the introduction of a work-share initiative with Health Canada (HC) under Policy 0070, aimed at improving efficiency while maintaining robust safeguards for sensitive information. The guidance Clinical Data Publication (CDP): Questions and Answers on EMA Polic

The UK clinical trial regulatory framework is undergoing a major transformation with the implementation of updated ICH E6 (R3) Good Clinical Practice (GCP) principles, alongside new guidance on quality, risk proportionality, and clinical investigations. The guidance Clinical trials for medicines: Compliance with ICH E6 Good Clinical Practice (GCP) in the United Kingdom, Clinical trials for medicines: guidance on quality and risk proportionality, and Clinical investigations fo

The FDA continues to strengthen regulatory expectations across both pharmaceutical quality and medical device oversight, with two important draft guidances issued in April 2026. The guidance Establishing Impurity Specifications for Antibiotics (April 2026, Draft) and Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators (April 20, 2026, Draft) provide structured recommendations for industry and regulators. Guidanc

The regulatory landscape for advanced therapies and patient access in the United States continues to evolve, with the FDA issuing updated guidances in April 2026 that address both cutting-edge genome editing safety and patient access to investigational treatments . Together, these guidances highlight the balance between innovation, safety evaluation, and ethical access to therapies across the product lifecycle. The guidance Safety Assessment of Genome Editing in Human Gene

The Guidance on the electronic submission of information on investigational medicinal products for human use in the Extended EudraVigilance medicinal product dictionary (XEVMPD) was updated on 13 April 2026 (Version 1.5) , providing detailed procedural and technical instructions for sponsors submitting clinical trial product data. Introduction This guidance provides consolidated instructions for sponsors on how to electronically submit information on investigational medici

The European regulatory landscape continues to evolve with a strong focus on supporting innovation in rare diseases and ensuring safe, evidence-based development of medicines for children . The European Medicines Agency (EMA) has issued two key procedural guidelines: Procedural advice for orphan medicinal product designation – Guidance for sponsors Procedural advice on paediatric applications – Guidance for applicants together, establish a comprehensive regulatory framewo

The guidance Clinical trials for medicines: Roles and responsibilities provides a comprehensive framework that outlines how responsibilities are distributed among stakeholders involved in clinical trials in the United Kingdom. Introduction Clinical trials in the UK are governed by a structured system where responsibilities are clearly defined to ensure participant safety, ethical conduct, and reliable data generation. This guidance outlines the roles of key stakeholders, inc

The global life sciences landscape is rapidly evolving with the integration of advanced artificial intelligence to accelerate drug discovery, genomics, and translational research . OpenAI has introduced a specialized model designed to address the complexity and scale of modern biomedical research workflows. The announcement Introducing GPT-Rosalind for life sciences research , published in April 2026 , presents a purpose-built AI model aimed at supporting scientific reasoning

The UK regulatory framework for clinical trials is undergoing a significant transition with the adoption of updated Good Clinical Practice (GCP) standards aligned with international expectations. The Medicines and Healthcare products Regulatory Agency (MHRA) is reinforcing compliance with ICH E6 (R3) to ensure high standards of participant safety, data integrity, and efficient trial conduct. The guidance Clinical trials for medicines: Guidance on compliance with ICH E6 Good

The South African regulatory framework for medical devices is strengthening its oversight to ensure full accountability across the supply chain , particularly when activities are outsourced to third parties. The South African Health Products Regulatory Authority (SAHPRA) has clarified that outsourcing does not reduce regulatory responsibility and that all parties involved must comply with licensing requirements. The guidance Licensing Requirements for Outsourced or Contracted

The U.S. regulatory landscape continues to evolve to ensure data reliability and scientific rigor in drug development, particularly in the growing use of biomarkers. As biomarkers become increasingly critical for evaluating drug safety and efficacy, the FDA has issued specific guidance to standardize how bioanalytical methods for these measurements should be validated. The guidance Bioanalytical Method Validation for Biomarkers was published in April 2026 , providing recom

The UK regulatory system for medicines continues to advance towards faster access, aligned decision-making, and patient-focused innovation . The Medicines and Healthcare products Regulatory Agency (MHRA) is strengthening its national procedures to ensure efficient evaluation of medicines while improving coordination with health technology assessment bodies. The guidance National assessment procedure for medicines was updated on 9 April 2026 , including the addition of a webi

The UK regulatory framework for medical devices continues to evolve with a strong focus on market transparency, safety, and clinical evidence generation . Recent updates from the Medicines and Healthcare products Regulatory Agency (MHRA) reinforce the importance of proper device registration and clinical investigation oversight to ensure patient safety and regulatory compliance. The guidance Register medical devices to place on the market was updated on 10 April 2026 , in

The European regulatory framework continues to strengthen data protection and transparency in its international collaborations, particularly when engaging with EU candidate countries. As part of this effort, the European Medicines Agency (EMA) has established clear guidelines on how personal data is processed within cooperation programmes. The guidance European Medicines Agency’s Data Protection Notice for the implementation of the Instrument for Pre-accession Assistance (I